| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 公司主要从事环保材料产业、电子信息材料产业、新能源材料产业和生命科学与医药产业四个领域产品的研发、生产和销售。其中，公司在环保材料产业、电子信息材料产业、新能源材料产业领域的产品均为功能性材料。公司在环保材料产业、电子信息材料产业方面的经营模式主要为定制生产模式，在新能源材料产业、生命科学与医药产业方面的经营模式主要为市场导向与定制相结合的生产模式。 公司自成立以来一直专注于化学合成技术的研发与产业化应用，依托于强大的研发团队和自主创新能力，公司年均开发产品数百种，根据最新统计，现拥有超过8,000种化合物的生产技术，其中超过3,000种产品已投入市场，获得国内外发明专利580余项。凭借在化学合成领域的研发创新、专有技术、产业化应用、生产过程控制、关键参数控制及安环管理、职业健康等方面的技术和经验积累，公司建立了以化学合成技术的研发与产业化应用为主导的科技创新平台。公司科技创新平台主要工艺涵盖了有机合成、无机合成、高分子聚合、纯化等多大类工艺，同时公司拥有多家在业内具备一定规模与影响力的专业化子公司。公司建立了具备国际互认资质的权威性分析测试中心，并已通过中国合格评定国家认可委员会（CNAS）认可，为公司高质量发展提供必要保障。未来公司将进一步强化新产品研发与产业化效率，提升公司核心竞争力，力争将公司打造成为世界先进化学材料制造者。 在功能性材料方面，公司依托于在化学合成领域的科技创新与技术积累及延伸，先后涉足了液晶材料、沸石系列环保材料、OLED材料等多个领域，并已在上述公司所涉足产品领域取得了业内领先地位；近年来公司在聚酰亚胺材料、半导体制造材料、新能源材料等多个领域积极布局；公司于2022年启动“中节能万润（蓬莱）新材料一期建设项目”用于扩增公司功能性材料产能，该项目目前正在积极推进中。未来公司将继续以科技创新为驱动，积极布局更多新材料领域，并力争取得更多新材料领域的业内领先地位。 在生命科学与医药产业方面，公司经过多年对医药市场的开拓和医药技术的储备，涉足了医药中间体、原料药、成药制剂、生命科学、体外诊断等多个领域。公司“药业制剂二车间项目”已于报告期内投入使用，该车间投入使用将为公司医药领域产品的发展贡献力量。未来，公司将采用自主研发、合作研发等多种方式，增强公司生命科学与医药产业竞争实力；同时，公司也将不断提高医药方面的技术能力与水平，依托化学合成领域的技术和经验积累，积极与国际知名医药企业开展基于CMO、CDMO模式的原料药项目，为建设成为全球一流的、提供完善的CMO、CDMO服务的生产基地奠定基础。 | ||||||||||||||||||||||||
| Main Business | 从事环保材料产业、电子信息材料产业、新能源材料产业和生命科学与医药产业四个领域产品的研发、生产和销售。 | ||||||||||||||||||||||||
| Legal Representative | 黄以武 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 于书敏 | ||||||||||||||||||||||||
| Solicitors | 北京市嘉源律师事务所 | ||||||||||||||||||||||||
| Auditors | 瑞华会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0535-6382740;0535-6101017 | ||||||||||||||||||||||||
| Fax No | 0535-6101018 | ||||||||||||||||||||||||
| Website | www.valiant.cecep.cn | ||||||||||||||||||||||||
| wanrun@valiant-cn.com；yushumin@valiant-cn.com;xiaoxl@valiant-cn.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 20/12/2011 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.840 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.300 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 7.518 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 9.992B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |